A new drug which is set to cut the risk of stroke in certain patients has been developed by Pfizer Inc. (NYSE:PFE).
New Stroke Drug From Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) and Bristol-Myers Squibb have been working on an experimental new drug that reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, reports said on Tuesday.
The drug, Apixaban, is an anticoagulant aimed at helping reduce the chances of stroke in patients with a common heart arrhythmia called atrial fibrillation (AF).
Apixaban will hopefully be a vast improvement over its predecessor Wafarin.
Pfizer Inc. Stock Info
As of 8/31/2010 (Last trade – 4:01pm), the Pfizer Inc. (NYSE:PFE) stocks are sitting at 15.91.
Over the past three months there has been a 6.1% change in the Pfizer Inc. (NYSE:PFE) stock price.
Last Price: 15.91
52 Week Low / High: 14 / 20.36
Market Cap: 127890000
Consensus Analyst Opinion: Moderate Buy
Zack’s Industry Rank: 2 out of 15
We’ll be keeping a close eye on the Pfizer Inc. (NYSE:PFE) stock price for developments over the next few weeks.
Pfizer Inc. (NYSE:PFE)
Pfizer is a bio-pharmaceutical company deriving its highly innovative products through R&D and years of experience, with which it hopes to improve health and well-being at every stage of life.
